BioMarin prices its hemophilia gene therapy at about US$1.5M following European approval by Editor | Aug 26, 2022 | Government, Regulatory & Policy News, LATEST NEWS, Pharmaceuticals & Manufacturing, WORLD NEWS | 0 USA- California-based biotechnology company BioMarin has announced that European regulators have... Read More
Biomarin plans to resubmit its experimental gene therapy to the FDA by Editor | Jan 11, 2022 | Government, Regulatory & Policy News, Hospitals, LATEST NEWS, Science, Technology & Research, WORLD NEWS | 0 USA – BioMarin Pharmaceutical plans to submit clinical trial results to the Food and Drug... Read More
FDA approves first therapy for dwarfism by Editor | Nov 22, 2021 | Government, Regulatory & Policy News, Hospitals, LATEST NEWS, WORLD NEWS | 0 USA – BioMarin Pharmaceutical Inc’s once-daily injection for children with the most... Read More